Lipid patterns in treated growth hormone deficient children vs. short stature controls

Journal of Pediatric Endocrinology and Metabolism

Volumn 27, Issue 9-10, 2014, Pages 909-914

  Foster, Christy ^a   Burton, Amy ^b   Scholl, Jenni ^a   Scott, Mary Lauren ^a   Gunter, Victoria ^c   McCormick, Kenneth ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE

Author keywords

cardiovascular risk; growth hormone; lipids; VAP panel

Indexed keywords

APOLIPOPROTEIN B; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; RECOMBINANT GROWTH HORMONE; GROWTH HORMONE;

ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GROWTH HORMONE DEFICIENCY; HUMAN; LIPID BLOOD LEVEL; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RECOMBINANT GROWTH HORMONE DEFICIENCY; SHORT STATURE; ADOLESCENT; BLOOD; BODY COMPOSITION; BODY HEIGHT; CASE CONTROL STUDY; CHILD; DRUG EFFECTS; DWARFISM, PITUITARY; FEMALE; HORMONE SUBSTITUTION; MALE; TREATMENT OUTCOME;

ADOLESCENT; BODY COMPOSITION; BODY HEIGHT; CASE-CONTROL STUDIES; CHILD; DWARFISM, PITUITARY; FEMALE; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; LIPIDS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84906971102     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2013-0488     Document Type: Article

References (35)

1. Abdu TA, Neary R, Elhadd TA, Akber M, Clayton RN. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 2001;55:209-16. 10.1046/j.1365-2265.2001.01320.x
2. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS. et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998;83:382-95. 10.1210/jcem.83.2.4594
3. Colao A, Di Somma C, Savanelli MC, De Leo M, Lombardi G. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 2006;16 Suppl A:S41-8. 1669033810.1016/j.ghir.2006.03.006
4. Di Somma C, Pivonello R, Pizza G, De Rosa A, Lombardi G, et al. Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. J Endocrinol Invest 2010;33:171-7. 1979429710.1007/BF03346577http://gateway.webofknowledge.com/gateway/Gateway.cgiGWVersion=2&SrcApp=PARTNERAPP&SrcAuth=LinksAMR&KeyUT=000277780200007&DestLinkType=FullRecord&DestApp=ALLWOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
5. Utz AL, Yamamoto A, Hemphill L, Miller KK. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J Clin Endocrinol Metab 2008;93:2507-14. 18445664http://gateway.webofknowledge.com/gateway/Gateway.cgiGWVersion=2&SrcApp=PARTNERAPP&SrcAuth=LinksAMR&KeyUT=000257513700017&DestLinkType=FullRecord&DestApp=ALLWOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1210/jc.2008-0169
6. Arai Y, Kojima T, Takayama M, Hirose N. The metabolic syndrome, IGF-1, and insulin action. Mol Cell Endocrinol 2009;299:124-8.
7. de Boer H, Blok GJ, Voerman HJ, Phillips M, Schouten JA. Serum lipid levels in growth hormone-deficient men. Metabolism 1994;43:199-203. 10.1016/0026-0495(94)90245-38121302
8. Vahl N, Klausen I, Christiansen JS, Jorgensen JO. Growth hormone (GH) status is an independent determinant of serum levels of cholesterol and triglycerides in healthy adults. Clin Endocrinol (Oxf) 1999;51:309-16. 10.1046/j.1365-2265.1999.00772.x
9. Imrie H, Abbas A, Viswambharan H, Rajwani A, Cubbon RM, et al. Vascular insulin-like growth factor-I resistance and diet-induced obesity. Endocrinology 2009;150:4575-82.
10. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002;106:939-44. 1218679710.1161/01.CIR.0000027563.44593.CC
11. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004;89:114-120. 10.1210/jc.2003-030967
12. De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab 1992;75:833-837. 1517374
13. Makimura H, Feldpausch MN, Stanley TL, Sun N, Grinspoon SK. Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size. Clin Endocrinol (Oxf) 2012;76:220-7. 10.1111/j.1365-2265.2011.04195.x
14. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991;11:174-82. 10.1161/01.ATV.11.1.1741987996
15. O'Brien T, Nguyen TT, Hallaway BJ, Hodge D, Bailey K, et al. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol 1995;15:228-31. 10.1161/01.ATV.15.2.228
16. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95:69-75. 10.1161/01.CIR.95.1.69
17. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 2008;14:S328; quiz S30-21.
18. Rudling M, Angelin B. Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice. FASEB J 2001;15:1350-6. 10.1096/fj.00-0715com11387232
19. Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:2684-90. http://gateway.webofknowledge.com/gateway/Gateway.cgiGWVersion=2&SrcApp=PARTNERAPP&SrcAuth=LinksAMR&KeyUT=000251143300031&DestLinkType=FullRecord&DestApp=ALLWOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1161/ATVBAHA.107.156257
20. Deepak D, Daousi C, Javadpour M, Clark D, Perry Y, et al. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res 2010;20:220-5. 10.1016/j.ghir.2010.02.00220185347http://gateway.webofknowledge.com/gateway/Gateway.cgiGWVersion=2&SrcApp=PARTNERAPP&SrcAuth=LinksAMR&KeyUT=000278652100007&DestLinkType=FullRecord&DestApp=ALLWOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
21. Schneider HJ, Klotsche J, Wittchen HU, Stalla GK, Schopohl J, et al. Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin Endocrinol (Oxf) 2011;75:825-30. http://gateway.webofknowledge.com/gateway/Gateway.cgiGWVersion=2&SrcApp=PARTNERAPP&SrcAuth=LinksAMR&KeyUT=000296912900018&DestLinkType=FullRecord&DestApp=ALLWOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1111/j.1365-2265.2011.04137.x
22. Jallad RS, Liberman B, Vianna CB, Vieira ML, Ramires JA, et al. Effects of growth hormone replacement therapy on metabolic and cardiac parameters, in adult patients with childhood-onset growth hormone deficiency. Growth Horm IGF Res 2003;13:81-8. 1273592910.1016/S1096-6374(03)00006-6
23. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol 2005;152:67-75.
24. Claessen KM, Appelman-Dijkstra NM, Adoptie DM, Roelfsema F, Smit JW, et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 2013;98:352-61. 10.1210/jc.2012-294023162104http://gateway.webofknowledge.com/gateway/Gateway.cgiGWVersion=2&SrcApp=PARTNERAPP&SrcAuth=LinksAMR&KeyUT=000316210300071&DestLinkType=FullRecord&DestApp=ALLWOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
25. Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, et al. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 2013;168:745-53. http://gateway.webofknowledge.com/gateway/Gateway.cgiGWVersion=2&SrcApp=PARTNERAPP&SrcAuth=LinksAMR&KeyUT=000318003300012&DestLinkType=FullRecord&DestApp=ALLWOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
26. Christ ER, Chowienczyk PJ, Sonksen PH, Russel-Jones DL. Growth hormone replacement therapy in adults with growth hormone deficiency improves vascular reactivity. Clin Endocrinol (Oxf) 1999;51:21-5. 10.1046/j.1365-2265.1999.00805.x
27. Salerno M, Esposito V, Spinelli L, Di Somma C, Farina V, et al. Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy. Clin Endocrinol (Oxf) 2004;60:630-6.
28. Johannsson G, Albertsson-Wikland K, Bengtsson BA. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 1999; 84:4516-24.
29. Gleeson H, Barreto ES, Salvatori R, Costa L, Oliveira CR, et al. Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation. Clin Endocrinol (Oxf) 2007;66:466-74.
30. Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med 2006;26:787-802. 10.1016/j.cll.2006.07.00417110240
31. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95:2022-6. 913351010.1161/01.CIR.95.8.2022
32. Ciresi A, Amato MC, Criscimanna A, Mattina A, Vetro C, et al. Metabolic parameters and adipokine profile during GH replacement in children with GH deficiency. Eur J Endocrinol 2007;156:353-360.
33. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 2006;259:455-61.
34. Filipsson Nystrom H, Barbosa EJ, Nilsson AG, Norrman LL, Ragnarsson O, et al. Discontinuing long-term GH replacement therapy-a randomized, placebo-controlled crossover trial in adult GH deficiency. J Clin Endocrinol Metab 2012;97:3185-95. 10.1210/jc.2012-200622791760
35. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198-208. 10.1542/peds.2008-134918596007